AbbVie (ABBV) 8-K Guidance Including the Impact of Acquired IPR&D and Milestones Expense

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

(in millions, except per share data)	Quarter Ended December 31, 2024						Full-Year Ended December 31, 2024
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q4 2024 acquired IPR&D and milestones expense	$	—	$	2.94	$	2.98	$	1,183	$	10.90	$	10.94
Q4 2024 acquired IPR&D and milestones expense	1,574		(0.88)		(0.88)		1,574		(0.88)		(0.88)
Guidance including Q4 2024 Acquired IPR&D and milestones expense	$	1,574	$	2.06	$	2.10	$	2,757	$	10.02	$	10.06

    1